['prostate cancer']
['galeterone', 'enzalutamide']

        Inclusion Criteria:

          -  Progressive metastatic (M1) disease on androgen deprivation therapy

          -  Detectable AR-V7 from circulating tumors (CTCs)

          -  ECOG performance status 0 or 1

        Exclusion Criteria:

          -  Prior treatment with second generation anti-androgens (e.g. abiraterone, enzalutamide)

          -  Prior treatment with chemotherapy for CRPC
      